To validate the clinical relevance of these findings and evaluate the therapeutic potential of immunomodulation, we established a pilocarpine-induced mouse model of hyperhidrosis and assessed the effects of SR2211, a selective RORγ antagonist (MedChemExpress, Cat# HY-16998, purity 99.67%) with low reported off-target activity against RORα, RORβ, and kinases such as TRK and BRAF. Here, BRAF is linked to Hyperhidrosis.